Quantcast
Last updated on April 16, 2014 at 13:31 EDT

Latest Thrombosis Stories

2012-09-24 23:00:50

NuvaRing Lawsuit Alleges Merck & Co., Organon USA, Inc., and other Defendants Failed to Warn Plaintiff of Serious NuvaRing Side Effects, Including a Higher Risk of Clots, Such as Deep Vein Thrombosis and Pulmonary Embolism, Compared to Birth Control Pills. Mellville, New York (PRWEB) September 24, 2012 Alonso Krangle LLP, an national law firm focused on fighting for the rights of serious personal injury victims of harmful drug side effects, announce they have filed a NuvaRing side...

2012-09-18 13:55:09

A study of patients treated with the anticoagulant medication warfarin suggests that resuming warfarin therapy after an episode of gastrointestinal tract bleeding was associated with lower risk for thrombosis (blood clot) and death, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication. Gastrointestinal tract bleeding (GIB) affects about 4.5 percent of patients treated annually with warfarin. A history of major bleeding can be a predictor...

2012-09-05 21:16:37

American Heart Association rapid access journal report Taking vitamin D supplements to compensate for vitamin D deficiency didn't improve cholesterol – at least in the short term, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal. Researchers studied 151 people with vitamin D deficiency who received either a mega-dose (50,000 internationals units) of vitamin D3 or placebo weekly for eight weeks. Participants'...

2012-09-04 06:25:32

Some Smaller Clots May Not Require Potentially Risky Treatment ROSEMONT, Ill., Sept. 4, 2012 /PRNewswire-USNewswire/ -- Men and women who undergo joint replacement procedures, as well as those who have significant fractures, tend to be at an increased risk of developing pulmonary emboli (PE), blood clots that travel to the lungs where they may cause serious complications and even death. Patients are often aggressively treated with anticoagulants, or blood thinners, to help prevent the...

2012-09-02 23:03:17

Blau, Brown & Leonard, LLC, are investigating the possible link of the drug Androgel to various blood clot disorders in men, including Pulmonary Embolisms and Deep Vein Thrombosis. The law firm has a 24/7 phone number at (800) 9100-LAW for anyone who has experienced such a side effect from Androgel. New York, NY (PRWEB) September 02, 2012 Blau, Brown & Leonard, LLC a law firm that litigates pharmaceutical cases nationwide is investigating the link between Androgel and certain blood...

2012-07-24 10:20:48

CRESSKILL, N.J., July 24, 2012 /PRNewswire/ -- Bayer, the German chemical and pharmaceutical manufacturer, has settled another 1000 Yaz and Yasmin related lawsuits since the April report, raising the amount Bayer has agreed to pay out to $300 million. An additional 7,500 suits are expected to be settled by year's end according to the federally appointed mediator working on the cases (source). However, disbursement of settlement funds to plaintiffs and their attorneys may take months, if not...

2012-07-18 01:17:57

Cedars-Sinai researchers have linked Kawasaki Disease, a serious childhood illness that causes inflammation of blood vessels throughout the body, with early-onset and accelerated atherosclerosis, a leading cause of heart disease in adults. In a study published in the August 2012 print edition of Arteriosclerosis, Thrombosis, and Vascular Biology, an American Heart Association peer-reviewed medical journal, a team of researchers showed how Kawasaki Disease in young mice predisposed them to...

2012-06-25 23:01:08

According to the US Drug Watchdog, "We are now offering to help women who used the birth control pills called Yaz, Yasmin, and Ocella, and then had a heart attack, blood clot, or other very serious health side affects get to the best attorneys." According to the New York Times, "In September of 2009, the US FDA released a warning letter sent to Bayer Pharmaceuticals over Yaz & Yasmin. The letter indicates that the drug maker hid out-of-specification test results for key ingredients in the...

2012-06-11 02:25:57

RESEARCH TRIANGLE PARK, N.C., June 11, 2012 /PRNewswire/ -- Grifols, a global healthcare company based in Barcelona, Spain, today announced publication of phase 1 study results demonstrating good safety and tolerability for the investigational therapy plasmin in treating patients with blood clots in the lower extremities, known as acute peripheral arterial occlusion (aPAO). These clots can block blood flow and thus result in nerve damage, limb amputation or potentially loss of life if not...

2012-05-14 02:25:33

LONDON, May 14, 2012 /PRNewswire/ -- The increasing incidence of thrombosis, paralleled by the maturing life cycles of existing products, are motivating the need for novel alternatives. Establishing end-user confidence and ensuring cost-effectiveness pose significant challenges to market advancement. However, the launch of three blockbuster oral anticoagulants is projected to help the thrombosis therapeutics market address these challenges. It is also anticipated to help companies tackle...